Zafgen Inc. (NASDAQ:ZFGN) shares dropped 1% on Tuesday . The stock traded as low as $6.72 and last traded at $6.85, with a volume of 184,623 shares. The stock had previously closed at $6.92.

ZFGN has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a research note on Thursday, May 12th. FBR & Co restated a “buy” rating and set a $20.00 price objective on shares of Zafgen in a research note on Monday, April 4th. Leerink Swann restated a “market perform” rating and set a $6.00 price objective on shares of Zafgen in a research note on Thursday, March 17th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $19.00 price objective on shares of Zafgen in a research note on Tuesday, April 5th. Four equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $11.94.

The firm’s market capitalization is $186.54 million. The stock’s 50 day moving average price is $6.46 and its 200-day moving average price is $6.58.

Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.09. During the same quarter in the prior year, the business earned ($0.53) earnings per share. On average, analysts expect that Zafgen Inc. will post ($2.81) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Zafgen stock. Oxford Asset Management acquired a new position in Zafgen Inc. (NASDAQ:ZFGN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 236,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,497,000. Oxford Asset Management owned about 0.87% of Zafgen as of its most recent filing with the SEC.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.